• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability.

作者信息

Casagrande Naike, Borghese Cinzia, Aldinucci Donatella

机构信息

Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN).

出版信息

Haematologica. 2022 Jan 1;107(1):287-291. doi: 10.3324/haematol.2021.279389.

DOI:10.3324/haematol.2021.279389
PMID:34498447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8719077/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b36/8719077/420d0511244d/107287.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b36/8719077/5d97011310c3/107287.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b36/8719077/68d66e72eb38/107287.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b36/8719077/420d0511244d/107287.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b36/8719077/5d97011310c3/107287.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b36/8719077/68d66e72eb38/107287.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b36/8719077/420d0511244d/107287.fig3.jpg

相似文献

1
In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability.在经典型霍奇金淋巴瘤中，CCR5拮抗剂马拉维若与曲贝替定联合使用具有协同作用，可增强DNA损伤并降低三维肿瘤-基质异质球体的活力。
Haematologica. 2022 Jan 1;107(1):287-291. doi: 10.3324/haematol.2021.279389.
2
CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.马拉维若（CCR5 拮抗剂）抑制霍奇金淋巴瘤微环境相互作用和异种移植物生长。
Haematologica. 2019 Mar;104(3):564-575. doi: 10.3324/haematol.2018.196725. Epub 2018 Oct 11.
3
In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin.在卵巢癌中，马拉维若能增强曲贝替定的抗肿瘤活性，并进一步抑制肿瘤促进微环境的形成。
Biomed Pharmacother. 2024 Mar;172:116296. doi: 10.1016/j.biopha.2024.116296. Epub 2024 Feb 20.
4
Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma.曲贝替定克服多柔比星耐药性，逆转单核细胞的肿瘤免疫抑制重编程，并降低霍奇金淋巴瘤的异种移植瘤生长。
Cancer Lett. 2021 Mar 1;500:182-193. doi: 10.1016/j.canlet.2020.12.015. Epub 2020 Dec 14.
5
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.马拉维若与 CCR5 抗体 HGS004 协同抑制原发性细胞中的 R5 HIV-1：对治疗和预防的影响。
AIDS. 2011 Jun 1;25(9):1232-5. doi: 10.1097/QAD.0b013e3283471edb.
6
Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.融合蛋白（FLSC）IgG1 Fc与马拉维若协同抑制原代细胞中的R5型HIV-1：对预防和治疗的意义
Curr HIV Res. 2016;14(1):24-36. doi: 10.2174/1570162x13666150909145150.
7
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.马拉维若：用于治疗 CCR5 嗜性 HIV-1 感染的综述。
Drugs. 2010 Jun 18;70(9):1189-213. doi: 10.2165/11203940-000000000-00000.
8
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.在少数接受CCR5拮抗剂马拉维若治疗的HIV-1感染患者中，出现利用CXCR4的1型人类免疫缺陷病毒（HIV-1）变体，这些变体来自治疗前利用CXCR4的病毒储存库。
J Virol. 2006 May;80(10):4909-20. doi: 10.1128/JVI.80.10.4909-4920.2006.
9
Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.马拉维若：一种用于治疗HIV感染的共受体CCR5拮抗剂。
Am J Health Syst Pharm. 2009 Apr 15;66(8):715-26. doi: 10.2146/ajhp080206.
10
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.一种对马拉维若耐药的 HIV-1 对其他 CCR5 拮抗剂的交叉耐药性较窄，这取决于药物结合的 CCR5 的 N 端和细胞外环结构域。
J Virol. 2010 Oct;84(20):10863-76. doi: 10.1128/JVI.01109-10. Epub 2010 Aug 11.

引用本文的文献

1
Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy.曲贝替定和洛布西尼调节肿瘤微环境中细胞间的相互作用-在联合癌症治疗中的应用进展。
Molecules. 2024 Jan 9;29(2):331. doi: 10.3390/molecules29020331.
2
In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869.在多柔比星适应的霍奇金淋巴瘤细胞中，获得多药耐药性和改善的免疫抑制能力后，氯喹和 GW4869 增强了多柔比星的活性。
Cells. 2023 Nov 29;12(23):2732. doi: 10.3390/cells12232732.
3

本文引用的文献

1
Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma.曲贝替定克服多柔比星耐药性，逆转单核细胞的肿瘤免疫抑制重编程，并降低霍奇金淋巴瘤的异种移植瘤生长。
Cancer Lett. 2021 Mar 1;500:182-193. doi: 10.1016/j.canlet.2020.12.015. Epub 2020 Dec 14.
2
Hodgkin lymphoma.霍奇金淋巴瘤。
Nat Rev Dis Primers. 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6.
3
The CCL5/CCR5 Axis in Cancer Progression.癌症进展中的CCL5/CCR5轴
The Medium Obtained from the Culture of Hodgkin Lymphoma Cells Affects the Biophysical Characteristics of a Fibroblast Cell Model.
从霍奇金淋巴瘤细胞培养中获得的培养基影响成纤维细胞模型的生物物理特性。
Bioengineering (Basel). 2023 Feb 3;10(2):197. doi: 10.3390/bioengineering10020197.
4
HIV Infection, Chromosome Instability, and Micronucleus Formation.人类免疫缺陷病毒感染、染色体不稳定性和微核形成。
Viruses. 2023 Jan 4;15(1):155. doi: 10.3390/v15010155.
5
Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma.针对患有霍奇金淋巴瘤的儿童和青少年患者的有前景的药物及治疗选择。
Front Cell Dev Biol. 2022 Nov 24;10:965803. doi: 10.3389/fcell.2022.965803. eCollection 2022.
6
Consecutive Inhibition of Telomerase and Alternative Lengthening Pathway Promotes Hodgkin's Lymphoma Cell Death.端粒酶和替代延长途径的连续抑制促进霍奇金淋巴瘤细胞死亡。
Biomedicines. 2022 Sep 16;10(9):2299. doi: 10.3390/biomedicines10092299.
7
Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review.复发难治性经典型霍奇金淋巴瘤的新型治疗药物：综述
Front Oncol. 2022 Jul 14;12:929012. doi: 10.3389/fonc.2022.929012. eCollection 2022.
8
Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma.研究经典型霍奇金淋巴瘤中微环境相互作用和药物活性的当前及新出现的方法
Cancers (Basel). 2022 May 14;14(10):2427. doi: 10.3390/cancers14102427.
Cancers (Basel). 2020 Jul 2;12(7):1765. doi: 10.3390/cancers12071765.
4
Clinical significance of chemokine receptor antagonists.趋化因子受体拮抗剂的临床意义。
Expert Opin Drug Metab Toxicol. 2020 Jan;16(1):11-30. doi: 10.1080/17425255.2020.1711884. Epub 2020 Jan 17.
5
Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury.结节硬化型经典型霍奇金淋巴瘤中的成纤维细胞具有特定表型，并能保护肿瘤细胞免受维布妥昔单抗诱导的损伤。
Cancers (Basel). 2019 Oct 30;11(11):1687. doi: 10.3390/cancers11111687.
6
Enriching cancer pharmacology with drugs of marine origin.从海洋来源的药物中丰富癌症药理学。
Br J Pharmacol. 2020 Jan;177(1):3-27. doi: 10.1111/bph.14876. Epub 2019 Dec 23.
7
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.针对癌症的 CCR5 靶点及在免疫肿瘤学中的作用的最新进展
Cancer Res. 2019 Oct 1;79(19):4801-4807. doi: 10.1158/0008-5472.CAN-19-1167. Epub 2019 Jul 10.
8
Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics.马拉维若与 ABCB1、ABCG2 和 ABCC2 转运体的相互作用：在胎盘药代动力学中的重要作用。
Drug Metab Dispos. 2019 Sep;47(9):954-960. doi: 10.1124/dmd.119.087684. Epub 2019 Jul 2.
9
Improved identification of DNA double strand breaks: γ-H2AX-epitope visualization by confocal microscopy and 3D reconstructed images.DNA双链断裂识别的改进：通过共聚焦显微镜和三维重建图像进行γ-H2AX表位可视化
Radiat Environ Biophys. 2019 May;58(2):295-302. doi: 10.1007/s00411-019-00778-1. Epub 2019 Feb 24.
10
CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.马拉维若（CCR5 拮抗剂）抑制霍奇金淋巴瘤微环境相互作用和异种移植物生长。
Haematologica. 2019 Mar;104(3):564-575. doi: 10.3324/haematol.2018.196725. Epub 2018 Oct 11.